Search results for "ARTICLES"

showing 10 items of 9626 documents

Acute kidney injury in heart failure: a population study

2020

Abstract Aims The objective of the present study is to assess the prognostic value of acute kidney injury (AKI) in the evolution of patients with heart failure (HF) using real‐world data. Methods and results Patients with a diagnosis of HF and with serial measurements of renal function collected throughout the study period were included. Estimated glomerular filtration rate (GFR) was calculated with the CKD‐EPI (Chronic Kidney Disease Epidemiology Collaboration). AKI was defined when a sudden drop in creatinine with posterior recovery was recorded. According to the Risk, Injury, Failure, Loss, and End‐Stage Renal Disease (RIFLE) scale, AKI severity was graded in three categories: risk [1.5‐…

medicine.medical_specialtyRenal functionHeart failure030204 cardiovascular system & hematologyRisk of hospitalization03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineOriginal Research ArticlesRisk of mortalitymedicineHumansDiseases of the circulatory (Cardiovascular) system030212 general & internal medicineOriginal Research ArticleRetrospective StudiesFirst episodeCreatininebusiness.industryIncidence (epidemiology)Hazard ratioAcute kidney injurymedicine.disease3. Good healthAcute kidney injurychemistryRisk of mortalityCreatinineRC666-701CardiologyFemaleCardiology and Cardiovascular MedicinebusinessKidney diseaseGlomerular Filtration RateRenal functionESC Heart Failure
researchProduct

Effects of intravenous furosemide plus small-volume hypertonic saline solutions on markers of heart failure.

2021

Aims: We sought to compare the effects of furosemide + hypertonic saline solution (HSS) treatment in patients with acute decompensated heart failure in comparison with furosemide alone and the response in a compensated state after an acute saline load with regard to serum levels of heart failure biomarkers. Methods and results: We enrolled 141 patients with acute decompensated heart failure with reduced ejection fraction admitted to our Internal Medicine ward from March 2017 to November 2019. A total of 73 patients were randomized to treatment with i.v. high-dose furosemide plus HSS, whereas 68 patients were randomized to i.v. high-dose furosemide alone. Patients treated with furosemide plu…

medicine.medical_specialtySettore MED/09 - Medicina InternaAcute decompensated heart failuremedicine.medical_treatmentfurosemide Heart failure HSS BiomarkersGastroenterologyFurosemideInternal medicineOriginal Research ArticlesmedicineDiseases of the circulatory (Cardiovascular) systemHumansOriginal Research ArticleHSSDiureticsSalineHeart FailureSaline Solution HypertonicEjection fractionTroponin Tbusiness.industryTherapeutic effectFurosemideAcute decompensated heart failuremedicine.diseaseHypertonic salineRC666-701Heart failureCardiology and Cardiovascular MedicinebusinessBiomarkersmedicine.drugESC heart failure
researchProduct

Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospect…

2014

Summary Background Body-mass index (BMI) and diabetes have increased worldwide, whereas global average blood pressure and cholesterol have decreased or remained unchanged in the past three decades. We quantified how much of the effects of BMI on coronary heart disease and stroke are mediated through blood pressure, cholesterol, and glucose, and how much is independent of these factors. Methods We pooled data from 97 prospective cohort studies that collectively enrolled 1·8 million participants between 1948 and 2005, and that included 57 161 coronary heart disease and 31 093 stroke events. For each cohort we excluded participants who were younger than 18 years, had a BMI of lower than 20 kg/…

medicine.medical_specialtySettore MED/09 - Medicina InternaNutrition and Diseasenoncommunicable diseasesbariatric surgeryscientific statementcardiovascular-diseaseCoronary DiseaseOverweightsystematic analysisBody Mass Indexblood-pressureInternal medicineDiabetes mellitusVoeding en ZiektemedicineHumansProspective cohort studyrisk-factorsStrokeVLAGHuman Nutrition & HealthGlobal NutritionWereldvoedingFramingham Risk Scorebusiness.industryHumane Voeding & GezondheidArticlesGeneral MedicineOverweightmedicine.diseaseObesityStrokeBlood pressurerandomized-trialsPhysical therapyCardiologyall-cause mortalitymedicine.symptombusinessBody mass indexbody-mass index obesity coronary heart disease strokeweight-loss
researchProduct

ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiova…

2017

Atherosclerotic cardiovascular disease still represents the leading cause of death in western countries. A wealth of scientific evidence demonstrates that increased blood cholesterol levels have a major impact on the outbreak and progression of atherosclerotic plaques. Moreover, several cholesterol-lowering pharmacological agents, including statins and ezetimibe, have proven effective in improving clinical outcomes. This document is focused on the clinical management of hypercholesterolemia and has been conceived by 16 Italian medical associations with the support of the Italian National Institute of Health. The authors have considered with particular attention the role of hypercholesterole…

medicine.medical_specialtySettore MED/09 - Medicina InternaPCSK9 inhibitorMEDLINE030204 cardiovascular system & hematologyNOatherosclerosis; diagnostic and therapeutic pathways; hypercholesterolaemia; PCSK9 inhibitors; statins; sustainable health careDiagnostic and therapeutic pathways03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEzetimibeInternal medicineDiabetes mellitusmedicine030212 general & internal medicineIntensive care medicineRisk managementCause of deathHypercholesterolaemiabusiness.industryAtherosclerotic cardiovascular diseaseCholesterolSustainable health careStatinsDiagnostic and therapeutic pathwayStatinHigh Cholesterol LevelsArticlesmedicine.diseaseAtherosclerosischemistryPCSK9 inhibitorsAtherosclerosiCardiologylipids (amino acids peptides and proteins)Atherosclerosis; Diagnostic and therapeutic pathways; Hypercholesterolaemia; PCSK9 inhibitors; Statins; Sustainable health care; Cardiology and Cardiovascular MedicineCardiology and Cardiovascular Medicinebusinessmedicine.drugEuropean Heart Journal Supplements : Journal of the European Society of Cardiology
researchProduct

A Rare Case of Giant Basal Cell Carcinoma of the Abdominal Wall: Excision and Immediate Reconstruction with a Pedicled Deep Inferior Epigastric Arter…

2017

Patient: Female, 82 Final Diagnosis: Giant basal cell carcinoma Symptoms: Anemia Medication: — Clinical Procedure: — Specialty: Plastic Surgery Objective: Rare disease Background: Basal cell carcinoma (BCC) greater than 5 cm in diameter is called giant basal cell carcinoma (GBCC), or super giant basal cell carcinoma if it has a diameter larger than 20 cm. Giant BCC only accounts for 0.5% of BCCs and super giant BCC is exceedingly rare. On account of their rarity, there are no established guidelines for GBCC treatment. Case Report: We describe a peculiar case of an 82-year-old woman with a GBCC carcinoma of the lower abdominal wall. The tumor was surgically removed with ipsilateral inguinal …

medicine.medical_specialtySkin NeoplasmsPropeller FlapSettore MED/19 - Chirurgia Plastica030204 cardiovascular system & hematologyAbdominal wall03 medical and health sciencesRare Diseases0302 clinical medicineDIEP flapRare casemedicineCarcinomaHumansNeoplasm InvasivenessBasal cell carcinomagiant basal cell carcinomaAged 80 and overSystemic complicationbusiness.industryAbdominal WallDeep Inferior Epigastric ArteryArticlesGeneral Medicinemedicine.diseaseMultiple pathologiesSurgerymedicine.anatomical_structureCarcinoma Basal CellFemalebusinessPerforator FlapBasal Cell Carcinoma030217 neurology & neurosurgeryAmerican Journal of Case Reports
researchProduct

Longitudinal imaging and evaluation of SAH-associated cerebral large artery vasospasm in mice using micro-CT and angiography

2019

Longitudinal in vivo imaging studies characterizing subarachnoid hemorrhage (SAH)-induced large artery vasospasm (LAV) in mice are lacking. We developed a SAH-scoring system to assess SAH severity in mice using micro CT and longitudinally analysed LAV by intravenous digital subtraction angiography (i.v. DSA). Thirty female C57Bl/6J-mice (7 sham, 23 SAH) were implanted with central venous ports for repetitive contrast agent administration. SAH was induced by filament perforation. LAV was assessed up to 14 days after induction of SAH by i.v. DSA. SAH-score and neuroscore showed a highly significant positive correlation (rsp = 0.803, p < 0.001). SAH-score and survival showed a negative sig…

medicine.medical_specialtySubarachnoid hemorrhageBiopsy030204 cardiovascular system & hematologySeverity of Illness IndexMice03 medical and health sciences0302 clinical medicineCerebral vasospasmIn vivomedicineAnimalsVasospasm Intracranialcardiovascular diseasesMicro ctmedicine.diagnostic_testbusiness.industryLarge arteryVasospasmOriginal ArticlesX-Ray MicrotomographyCerebral ArteriesSubarachnoid Hemorrhagemedicine.diseaseImmunohistochemistrynervous system diseasesCerebral AngiographyDisease Models AnimalNeurologyAngiographyFemaleNeurology (clinical)RadiologyCardiology and Cardiovascular MedicinebusinessBiomarkers030217 neurology & neurosurgeryPreclinical imagingJournal of Cerebral Blood Flow & Metabolism
researchProduct

The timing of introduction of pharmaceutical innovations in seven European countries

2014

RATIONALE, AIMS AND OBJECTIVES: Differences in the performance of medical care may be due to variation in the introduction and diffusion of medical innovations. The objective of this paper is to compare seven European countries (United Kingdom, the Netherlands, West Germany, France, Spain, Estonia and Sweden) with regard to the year of introduction of six specific pharmaceutical innovations (antiretroviral drugs, cimetidine, tamoxifen, cisplatin, oxalaplatin and cyclosporin) that may have had important population health impacts. METHODS: We collected information on introduction and further diffusion of drugs using searches in the national and international literature, and questionnaires to …

medicine.medical_specialtyTime FactorsAlternative medicinePopulation healthpharmaceuticalsMedical careWest germanyoutcome measuresNursingquality of careSurveys and QuestionnairesInternational literaturemedicineHumansPharmaceutical innovationsSales statisticsDrug ApprovalQuality of Health Carebusiness.industryHealth PolicyPublic Health Environmental and Occupational HealthOriginal ArticlesmortalityClinical trialEuropePharmaceutical Preparationsmedical careDiffusion of Innovationbusinesshealth systemsDemographyJournal of Evaluation in Clinical Practice
researchProduct

Renal function dynamics following co-administration of sacubitril/valsartan and empagliflozin in patients with heart failure and type 2 diabetes

2020

Abstract Aims The aim of this study was to evaluate the safety profile in terms of changes in renal function after co‐treatment with sacubitril/valsartan and empagliflozin in patients with type 2 diabetes (T2D) and heart failure with reduced ejection fraction (HFrEF). Methods and results This multicentre observational analysis included 108 patients with T2D and HFrEF treated with both agents: baseline sacubitril/valsartan (Group A; n = 43), baseline empagliflozin (Group B; n = 42), or both agents initiated simultaneously (Group C; n = 23). The primary endpoint was estimated glomerular filtration rate (eGFR) dynamics across treatment groups. A binary characterization of worsening renal funct…

medicine.medical_specialtyUrologyRenal function030204 cardiovascular system & hematologySacubitril03 medical and health scienceschemistry.chemical_compound0302 clinical medicineHeart failure with reduced ejection fraction (HFrEF)Original Research ArticlesRenal safety profileType 2 diabetes mellitusEmpagliflozinDiseases of the circulatory (Cardiovascular) systemMedicineSGLT2iOriginal Research Article030212 general & internal medicineSacubitril/valsartanCreatinineEjection fractionbusiness.industrymedicine.diseasechemistryValsartanRC666-701Heart failureCardiology and Cardiovascular MedicinebusinessSacubitril Valsartanmedicine.drugRenal function
researchProduct

Salmon-colored and white areas on dermoscopy as supportive findings in the diagnosis of primary cutaneous marginal zone lymphoma

2019

medicine.medical_specialtyWhite (horse)business.industryCancerlymphomaArticlesDermatologymedicine.diseaseDermatologyLymphomaOncologyRL1-803GeneticsmedicinecancerPrimary cutaneous marginal zone lymphomadermoscopybusinessMolecular BiologyDermatology Practical & Conceptual
researchProduct

Do we know more about hypertension in Poland after the May Measurement Month 2017?—Europe

2019

Abstract Elevated blood pressure (BP) is a worldwide burden, leading to over 10 million deaths yearly. May Measurement Month (MMM) is a global initiative organized by the International Society of Hypertension aimed at raising awareness of hypertension and the need for BP screening. An opportunistic cross-sectional survey of volunteers aged ≥18 was carried out in May 2017. BP measurement, the definition of hypertension and statistical analysis followed the globally approved MMM17 Study Protocol. In Poland 5834 (98.9%, Caucasian) individuals were screened. After multiple imputation, 2601 (35.3%) had hypertension. Of individuals not receiving anti-hypertensive medication, 976 (20.6%) were hype…

medicine.medical_specialtybusiness.industryArticles030204 cardiovascular system & hematologyOverweightmedicine.diseaseObesityElevated blood03 medical and health sciences0302 clinical medicineBlood pressureCardiovascular System & HematologyInternal medicinemedicineStatistical analysis030212 general & internal medicineSystoleUnderweightmedicine.symptomCardiology and Cardiovascular Medicinebusiness1102 Cardiorespiratory Medicine and HaematologyOpportunistic screeningEuropean Heart Journal Supplements
researchProduct